In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Neuroprotective Agents (4)

Edited by Edited by William Slikker, Jr. (National Center for Toxicological Research/FDA, Jefferson, AR), Russell J. Andrews (NASA Ames Research Center, San Jose, CA), and Bruce Trembly (Neurosurgery, VA Medical Center, Togus, ME)
Neuroprotective Agents (4)

Published: June 2003

Volume 993

Learn More

The sixth in this series of Annals volumes brings together clinical and basic science researchers from many countries and disciplines in a common forum to address various approaches to neuroprotection. Topics covered include the following: clinical trials; clinical application of neuroprotective approaches; NMDA receptors as mediators of neurotoxicity and neuroprotection; models, mediators, and mechanisms of neurotoxicity and neuroprotection; dietary supplements as neuroprotectants; oxidative stress and approaches to neuroprotection; mitochondria as a target of neurotoxicity and neuroprotection; and genomic approaches.